Engineered immune cells take on lupus and scleroderma
NCT ID NCT07155369
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 31 times
Summary
This study tests a new treatment using donor immune cells (CAR T-cells) that are designed to target and destroy faulty immune cells causing lupus and scleroderma. The goal is to control these severe autoimmune diseases when other treatments have failed. 18 adults with relapsed or refractory lupus or scleroderma will receive the therapy and be monitored for safety and disease improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Conditions
Explore the condition pages connected to this study.